HC Wainwright Issues Negative Estimate for EYPT Earnings

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Investment analysts at HC Wainwright reduced their Q3 2026 earnings estimates for shares of Eyepoint Pharmaceuticals in a note issued to investors on Tuesday, October 20th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.85) for the quarter, down from their previous forecast of ($0.60). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Eyepoint Pharmaceuticals’ current full-year earnings is ($3.51) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals’ FY2026 earnings at ($3.40) EPS and Q3 2027 earnings at $0.45 EPS.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The firm had revenue of $0.51 million for the quarter, compared to analysts’ expectations of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%.

A number of other equities analysts have also weighed in on the company. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Chardan Capital cut Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 price target on the stock. in a report on Tuesday, August 18th. Laidlaw restated a “hold” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Mizuho reiterated a “neutral” rating and set a $0.50 price objective on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Finally, Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $40.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Eyepoint Pharmaceuticals presently has an average rating of “Hold” and an average price target of $21.85.

Eyepoint Pharmaceuticals Stock Performance

Shares of EYPT stock opened at $0.43 on Thursday. The stock has a fifty day simple moving average of $4.25 and a two-hundred day simple moving average of $10.12. The firm has a market capitalization of $37.07 million, a PE ratio of -0.11 and a beta of 1.67. Eyepoint Pharmaceuticals has a 52-week low of $0.39 and a 52-week high of $19.11.

Institutional Trading of Eyepoint Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in shares of Eyepoint Pharmaceuticals during the 1st quarter worth approximately $29,000. Integrated Wealth Concepts LLC purchased a new stake in Eyepoint Pharmaceuticals during the second quarter valued at $72,000. Pictet Asset Management Holding SA purchased a new stake in Eyepoint Pharmaceuticals during the first quarter valued at $141,000. Engineers Gate Manager LP bought a new position in Eyepoint Pharmaceuticals during the second quarter valued at $161,000. Finally, Janney Montgomery Scott LLC grew its stake in shares of Eyepoint Pharmaceuticals by 14.8% in the 1st quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock worth $391,000 after buying an additional 3,900 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals News Summary

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Traders purchased a large volume of EYPT call options, signaling increased speculative interest and expectations that the stock could rebound or move sharply higher. Stock Traders Purchase Large Volume of Call Options on Eyepoint Pharmaceuticals
• Positive Sentiment: RBC identified the company’s upcoming diabetic macular edema (DME) study readout as a potential catalyst. Positive data could help offset the recent failure of an EyePoint wet age-related macular degeneration (wAMD) trial to meet its endpoint. EyePoint’s DME Study Readout a Catalyst After wAMD Trial Misses Endpoint
• Neutral Sentiment: Analyst sentiment remains mixed across EyePoint and other healthcare companies, reflecting uncertainty over the company’s clinical pipeline and future catalysts. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: Laidlaw reaffirmed its “hold” rating. RBC also maintained a “sector perform” view while cutting its price target to $1.00, and Mizuho reaffirmed “neutral” with a $0.50 target. These targets remain above the recent share price but indicate limited conviction.
• Negative Sentiment: Jefferies Financial Group lowered its rating on EyePoint, adding to pressure from a more cautious analyst outlook. Eyepoint Pharmaceuticals Stock Rating Lowered by Jefferies
• Negative Sentiment: Guggenheim also downgraded the stock, reinforcing concerns after the wAMD trial miss and highlighting the high-risk nature of EyePoint’s development program. Eyepoint Pharmaceuticals Stock Gets Downgrade from Guggenheim

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.